Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Ontology highlight
ABSTRACT: Triple negative breast cancer (TNBC) is an aggressive subset for which effective therapeutic approaches are needed. A significant proportion of TNBC patients harbor either germline or somatic mutations in BRCA1, or epigenetic silencing of BRCA1, which renders them deficient in DNA repair. Virtually all BRCA1 deficient breast cancers harbor mutations in TP53 suggesting that inactivation of p53 is a requirement for tumor progression in the setting of BRCA1 deficiency. Due to this dependency, we hypothesized that restoring wild type p53 function in BRCA1 deficient breast cancer would be therapeutic. The majority of TP53 mutations are missense, which generate a defective protein that potentially can be targeted with small molecules. Zinc metallo
SUBMITTER: Na B
PROVIDER: S-EPMC6465291 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA